Abstract
Extra Cytoplasmic Function (ECF) σ factors are a diverse group of alternate σ factors bacteria use to respond to changes in the environment. The Bacillus subtilis ECF σ factor σV responds to lysozyme. In the absence of lysozyme, σV is held inactive by the anti-σ factor, RsiV. In the presence of lysozyme RsiV is degraded via regulated intramembrane proteolysis, which results in the release of σV and thus activation of lysozyme resistance genes. Signal peptidase is required to initiate degradation of RsiV. Previous work indicated that RsiV only becomes sensitive to signal peptidase upon direct binding to lysozyme. We have identified a unique domain of RsiV that is responsible for protecting RsiV from cleavage by signal peptidase in the absence of lysozyme. We provide evidence that this domain contains putative amphipathic helices. Disruption of the hydrophobic surface of these helices by introducing positively charged residues results in constitutive cleavage of RsiV by signal peptidase and thus constitutive σV activation. We provide further evidence that this domain contains amphipathic helices using a membrane-impermeable reagent. Finally, we show that upon lysozyme binding to RsiV, the hydrophobic face of the amphipathic helix becomes accessible to a membrane-impermeable reagent. Thus, we propose the amphipathic helices protect RsiV from cleavage in the absence of lysozyme. Additionally, we propose the amphipathic helices rearrange to form a suitable signal peptidase substrate upon binding of RsiV to lysozyme leading to the activation of σV.
Author summary
Signal transduction involves (i) sensing a signal, (ii) a molecular switch triggering a response, and (iii) altering gene expression. For Bacillus subtilis’ response to lysozyme, we have a detailed understanding of (i) and (iii). Here we provide insights for a molecular switch that triggers the lysozyme response via σV activation. RsiV, an inhibitor of σV activity, is cleaved by signal peptidase only in the presence of lysozyme. Signal peptidase constitutively cleaves substrates that are translocated across the membrane. A domain-of-unknown-function (DUF4179) in RsiV contains the signal peptidase cleavage site, and protects RsiV from cleavage in the absence of lysozyme via amphipathic helices. In addition to RsiV, DUF4179 is found in an unrelated and uncharacterized anti-σ factor present in Firmicutes including within some clinically-relevant species.
Introduction
One key survival feature of all living organisms is the ability to recognize changes in their environments and respond appropriately. One signal transduction system bacteria use to sense and respond to environmental stresses are Extracytoplasmic Function (ECF) sigma (σ) factors [1,2]. ECF σ factors are a diverse family of alternative σ factors that are responsible for transcribing a wide variety of genes in response to environmental signals, often extracellular stress [3,4]. One hallmark of ECF σ factors is the presence of an anti-σ factor that is responsible for sequestering σ activity in the absence of signal. When bacteria encounter a specific signal, the anti-σ factor is inactivated via one of three mechanisms: 1) degradation of the anti-σ factor [3–5] 2) conformational change of the anti-σ factor [6–9] or 3) a partner switching mechanism in which an anti-anti-σ factor binds the anti-σ factor [10–13]. All three mechanisms result in the signal-dependent release of the σ factor and subsequent transcription of genes involved with the stress response.
Degradation of the anti-σ factor is frequently achieved by Regulated Intramembrane Proteolysis (RIP) [4,14,15], a stepwise proteolytic cascade. In most cases, cleavage occurs extracellularly at site-1 followed by an intramembrane site-2 protease. Cytosolic proteases degrade the remaining portion of the protein, releasing the σ factor to interact with RNA polymerase [4,14,15]. Cleavage at site-1 is typically the rate-limiting step of this cascade and thus is the regulated step of ECF σ factor activation [16–19]. A well-studied example of such regulation is the ECF σ factor σE in E. coli which is responsible for responding to cell envelope stress and is held inactive by the membrane bound anti-σ factor RseA [18,20]. Unfolded outer membrane proteins bind to the PDZ domain of DegS leading to the activation of DegS and cleavage of RseA at site-1 [21]. This cleavage event initiates the RIP cascade where RseA is further degraded by the intramembrane protease RseP and cytosolic proteases resulting in the activation of σE [14,19,22]. The B. subtilis ECF σ factor σW is another example where the rate-limiting step of anti-σ factor inactivation is proteolytic cleavage at site-1. RsiW is the anti-σ factor that holds σW in an inactive state in the absence of signal [17]. When cell envelope stresses are present, the site-1 protease PrsW cleaves RsiW and initiates a RIP cascade, resulting in the activation of σW [23,24].
In B. subtilis the ECF σ factor σV belongs to the ECF30 subfamily which is found primarily in low GC gram positive Firmicutes including C. difficile and E. faecalis [1]. σV is held inactive by its anti-σ factor RsiV and the inducing signal is C-type lysozyme [25]. Lysozyme is a component of the innate immune system that degrades peptidoglycan by cleaving β-(1,4)-linked N-acetylmuramic acid and N-acetylglucosamine [26–28]. σV is responsible for transcribing genes involved in lysozyme resistance including oatA which encodes an O-acetylase that adds an acetyl group to peptidoglycan increasing resistance to lysozyme cleavage [16,29–31]. The dltABCDE operon is also transcribed by σV and encodes genes responsible for modifying the charge of teichoic acid which presumably works to repel positively charged lysozyme [25,31–34]. In the absence of σV both C. difficile and E. faecalis become more sensitive to lysozyme [35,36].
Activation of σV occurs through RIP-mediated degradation of the anti-σ factor RsiV and occurs only in the presence of C-type lysozyme [16,37,38]. The current model of σV activation is shown in Fig 1A. Our lab has previously shown that signal peptidase is the site-1 protease responsible for removing the extracellular portion of RsiV [38]. After site-1 cleavage, the remaining transmembrane portion of RsiV is then degraded constitutively by the intramembrane metalloprotease RasP at site-2. The remaining cytoplasmic portion of RsiV is presumably degraded by cytosolic proteases [16]. RIP-mediated cleavage of RsiV leads to the release of σV and subsequent transcription of σV-controlled genes resulting in increased lysozyme resistance for the bacterium.
In bacteria, signal peptidases are associated with the secretion machinery and are critical for cell function [39,40]. Signal peptidases are typically responsible for cleaving secreted pre-proteins containing a signal peptide, thus releasing them from the membrane. Signal peptidase function is not known to be regulated and cleavage is believed to occur during or shortly after translocation [39–41]. The findings in B. subtilis then raise interesting questions: how is RsiV able to resist signal peptidase cleavage in the absence of lysozyme? What changes occur once lysozyme binds to create a suitable substrate for signal peptidase?
Here we provide evidence for the presence of amphipathic helices in RsiV that protect it from signal peptidase cleavage in the absence of lysozyme. We identified the region required to protect fusion proteins from signal peptidase cleavage. We determined that disruption of the putative amphipathic helices by introducing lysine residues results in constitutive cleavage by signal peptidase. We show using a membrane-impermeable reagent that the hydrophobic face of the amphipathic helixes can only be labeled in the presence of lysozyme. We also propose a model to explain how RsiV and lysozyme binding leads to a suitable signal peptidase substrate.
Results
RsiV residues 1–86 are sufficient for protection of a membrane-targeted GFP from signal peptidase cleavage
We previously demonstrated that RsiV is proteolytically degraded in a RIP-dependent manner in the presence of lysozyme leading to the activation of σV [16,37]. The protease required for site-1 cleavage of RsiV is signal peptidase [37,38]. However signal peptidase is only able to efficiently cleave RsiV in the presence of lysozyme [38]. It has been proposed that in the absence of lysozyme, RsiV is in a conformation that is resistant to signal peptidase cleavage. Upon binding to lysozyme, RsiV is hypothesized to undergo a conformational change that allows signal peptidase access to the cleavage site, leading to degradation of RsiV and subsequent σV activation [42]. Site-1 cleavage of RsiV by signal peptidase occurs between residues 66 and 67 [37]. To identify the key residues of RsiV sufficient for protection from signal peptidase, we fused the signal peptide of RsiV (amino acids 1–66) to GFP and expressed the fusion protein in B. subtilis. We predict that if the RsiV signal peptide is able to protect from signal peptidase cleavage, then the fusion of these residues to GFP would be sufficient to block secretion of GFP into the culture supernatant. We analyzed the RsiV1-66-GFP fusion by performing western blot analysis of the whole cells and concentrated culture supernatant using an anti-GFP antibody. We detected cleaved GFP in the culture supernatants from strains producing RsiV1-66-GFP suggesting the signal peptide alone is not sufficient to protect from signal peptidase (Fig 2A).
We then created constructs with various lengths of the RsiV N-terminus fused to GFP and expressed in B. subtilis to determine if additional residues after the signal peptide (RsiV1-76-GFP, RsiV1-86-GFP, and RsiV1-96-GFP) are sufficient to protect GFP from cleavage by signal peptidase. Cells producing these proteins were analyzed by western blot as described above. We found that cleaved GFP was present in the culture supernatant of strains producing RsiV1-66-GFP and RsiV1-76-GFP (Fig 2A). However, we did not detect a cleaved GFP band in the supernatant for RsiV1-86-GFP, or RsiV1-96-GFP. Importantly, we were able to detect uncleaved RsiV-GFP in whole cells confirming they were produced at similar levels (Fig 2A). These results suggest that residues 1–86 of RsiV are sufficient to protect from signal peptidase cleavage.
Residues after the cleavage site are required to protect RsiV from signal peptidase cleavage
Our data suggest that residues 1–86 are sufficient to protect the RsiV-GFP fusion proteins from signal peptidase cleavage, but residues 1–76 were not sufficient. To determine if the region after the signal peptidase cleavage site is required to protect RsiV from signal peptidase cleavage we constructed internal deletions of RsiV after the signal peptidase cleavage site; RsiVΔ67–76 and RsiVΔ67–86. To monitor signal peptidase cleavage of RsiV in the presence and absence of lysozyme, the cell pellets and culture supernatants were collected and analyzed by western blotting with anti-RsiV antibodies. Similar to the previous assay, if a cleavage product is detected in the supernatant it indicates that RsiV is being cleaved in the absence of lysozyme. Consistent with previous observations, wild-type (WT) RsiV was cleaved only in the presence of lysozyme (Fig 2B) [37]. In contrast for both deletion constructs a cleavage product was detected in the culture supernatant in the absence of lysozyme (Fig 2B).
We constructed the same deletions in a reporter strain to measure their impact on σV activity. We measured σV activity using a PsigV-lacZ promoter fusion which is dependent upon σV for expression [25,31]. We found, as expected, that RsiVΔ67–76 and RsiVΔ67–86 had increased basal levels of PsigV-lacZ expression indicating increased σV activation (Fig 2C). In addition, PsigV-lacZ was induced only ~2-fold by lysozyme when the region located after the cleavage site was deleted (Fig 2C). We also performed a western blot of the pellet and supernatant from the strains used in the σV activity assay and found similar results to IPTG expression strains (S4 Fig). WT RsiV was not cleaved while both RsiV deletion constructs were degraded in the absence of lysozyme (S4 Fig). Taken together, these results suggest that residues within 67–86 are required for the protection of RsiV from signal peptidase cleavage in the absence of lysozyme. We propose that residues surrounding the cleavage site of RsiV to amino acid 86 contain a region that is important for blocking signal peptidase cleavage of RsiV in the absence of lysozyme.
The protective region of RsiV is highly conserved among homologs
Based on our observation that residues 67–86 are necessary to protect against signal peptidase cleavage, we sought to characterize the region that is responsible for resistance to signal peptidase. An alignment of 203 RsiV homologs was used to create a sequence logo showing a high degree of homology for residues 61–84 (S1 Fig) [37,43,44]. The sequence logo also revealed an alternating pattern of hydrophobic and hydrophilic residues suggesting the presence of a potential amphipathic helix (Fig 1B). We used the secondary structure prediction software PEP-FOLD3 to predict the structure of this region in B. subtilis and we identified a predicted structure with two α-helices separated by a loop (Fig 1B) [45,46]. Upon investigation of the predicted structure, we identified a hydrophobic and hydrophilic face for each helix suggesting the predicted secondary structure contains two amphipathic helices. Helical wheel projections of each helix were created using NetWheels [47] and further suggest the presence of putative amphipathic helices containing both a hydrophobic and hydrophilic face (Fig 1B). The putative amphipathic helices are part of a domain of unknown function DUF4179 [48]. In the case of another DUF4179 member, the anti-σ factor BAS1627 from Bacillus anthracis the structure was solved (3FBQ) [49] revealing two α-helices separated by a turn much like our predicted structure (Fig 1B). Analysis of Pfam database revealed that the DUF4179 domain is largely restricted to the phyla Firmicutes (Table 1). RsiV and BAS1627 are members of the ECF30 family which are almost exclusively found in Firmicutes (48) and it appears the DUF4179 is restricted to these anti-sigma factor families.
Table 1. Phylum distribution of DUF4179*.
Phylum | Number of Species | Number of Sequences |
---|---|---|
Firmicutes | 203 | 702 |
Actinobacteria | 10 | 14 |
Chloroflexi | 2 | 3 |
Mucoromycota | 1 | 1 |
Streptophyta | 1 | 2 |
*as of June 27, 2018
Disruption of hydrophobic residues in the potential amphipathic helix leads to constitutive σV activation and RsiV degradation
Our in-silico analysis of RsiV revealed potential amphipathic helices that we hypothesized could be responsible for blocking signal peptidase cleavage in the absence of lysozyme. To test this hypothesis, we sought to disrupt the amphipathic helices by introducing a positive charge into the hydrophobic face. We constructed strains in which a hydrophobic residue of Helix 1 (M67), Helix 2 (I73, I76), or a residue directly after the predicted amphipathic helices (I80) were each changed to a lysine residue. The resulting constructs were analyzed for σV activity using the PsigV-lacZ reporter. We found that a lysine substitution at each hydrophobic residue resulted in dramatic (>100-fold) increase in the basal level of PsigV-lacZ expression in the absence of lysozyme (Fig 3A). When incubated with lysozyme (10 μg/ml), cells producing RsiVM67K showed only a modest ~2-fold increase while the remaining mutants showed no further increase (Fig 3A). Thus, changing select hydrophobic residues to positively charged lysine residues results in constitutive σV activity which suggests that RsiV is being cleaved by signal peptidase in the absence of lysozyme.
To ensure RsiV was being produced and to determine if it was being cleaved at site-1 by signal peptidase in the absence of lysozyme we measured RsiV levels both in the cells and in the culture supernatant by western blot using anti-RsiV antibodies. In each case we observed cleaved RsiV in the culture supernatants of cells producing RsiV with a lysine substitution but not WT RsiV (Fig 3B). In addition, we observed increased levels of RsiV in whole cell fractions of the cells producing RsiV with lysine substitutions (Fig 3B). This is likely due to increased activation of σV and thus increased expression of rsiV itself. These results suggest that changing the hydrophobic residues of these putative amphipathic helices to a positively charged residue leads to increased cleavage of RsiV in the absence of lysozyme.
To ensure that these mutations did not simply lead to misfolded RsiV, we used Circular Dichroism spectroscopy (CD) to compare the secondary structure of RsiVA66W I76K and RsiVA66W I80K to WT RsiV and RsiVA66W. The addition of RsiVA66W was necessary to allow for purification of the proteins without cleavage by signal peptidase. CD spectra showed troughs at 208 and 222 nm indicating helical secondary structure in the protein. Moreover, the CD spectra of all the variants are very similar to WT, suggesting that the lysine mutations do not result in protein with any gross change in secondary structure (S6 Fig). This supports a model in which an amphipathic helix protects RsiV cleavage in the absence of lysozyme and disruption of the amphipathic nature of these helices results in lysozyme independent cleavage of RsiV by signal peptidase.
Hydrophobic residues of the amphipathic helices are differentially labeled dependent on lysozyme
We hypothesize the hydrophobic face of the amphipathic helices are interacting with the cell membrane and this interaction is limiting signal peptidase access to the cleavage site. To test whether the hydrophobic residues are membrane embedded we used a Substituted Cysteine Accessibility Method (SCAM) assay which takes advantage of the fact that RsiV lacks endogenous cysteine residues. Before performing the SCAM assay, we first tested the effect of the various RsiV cysteine substitutions on σV activity by monitoring expression of the PsigV-lacZ promoter fusion in response to increasing concentrations of lysozyme. We found that the majority of cysteine substitutions did not alter activation of σV in response to lysozyme and behaved like WT RsiV (Fig 4A). Only one cysteine substitution (RsiVI73C) led to increased σV activity in the absence of lysozyme (4A). Additionally, we monitored RsiV degradation by testing both the pellet and supernatant of these constructs for RsiV by western blot analysis. Similar to the σV activity assay, only RsiVI73C was cleaved in the absence of lysozyme (Fig 4B). These results suggest that single cysteine substitutions of RsiV, except for RsiVI73C, do not impact σV activity and result in a functional RsiV.
To perform the SCAM assay we constructed a strain producing 6xHis-RsiVA66W. The 6xHis-tag was added to allow for purification of RsiV mutant proteins after labeling. The A66W mutant was necessary to allow for purification of RsiV after lysozyme addition as we previously demonstrated that RsiVA66W blocks site-1 cleavage [37,38]. We then introduced cysteine substitutions at various positions along the putative amphipathic helices of RsiV (Fig 1B). To label cysteine substitutions of 6xHis-RsiVA66W we used (Na-(3-maleimidylpropionyl) biocytin (MPB) [50,51]. MPB is a membrane-impermeable molecule with a biotin group that allows for detection using streptavidin conjugates and a maleimide group capable of covalently binding to cysteine [51,52]. Cells were either exposed to lysozyme (150 μg/ml) or left untreated. MPB (50 μM) was added to label extracellular cysteines. Next, RsiV was affinity purified using nickel resin. We then performed western blotting to analyze RsiV levels with anti-RsiV and MPB labeled RsiV was detected using Streptavidin IR680LT. As a negative control for MPB we included RsiVA66W which lacks cysteines and found that, as expected, we could not detect biotinylated RsiV. As a positive control, we introduced a cysteine at position 167 which is where RsiV interacts with lysozyme and we expect to be present extracellularly [42]. We found that RsiVA66W A167C was labeled when incubated in the presence and absence of lysozyme (Fig 5).
We observed that hydrophilic residues (Q65C, K69C, K78C, and E84C) could be labeled in both the presence and absence of lysozyme indicating these residues are outside of the membrane and accessible to label (Fig 5). Conversely, hydrophobic residues (M67C, I70C, V72C, I73C, I76C, and I80C) do not label in the absence of lysozyme suggesting they are embedded in the membrane when lysozyme is not present. In the presence of lysozyme these same hydrophobic residues are now labeled, indicating they are accessible to the label. F82C is a hydrophobic residue that labels in both the absence and presence of lysozyme indicating that it is not embedded in the membrane (Fig 5). Interestingly, F82 is not predicted to be part of the α-helices (Fig 1B) and was previously observed to be part of the β-sheet in the RsiV-Lysozyme co-structure [42]. These results further suggest the presence of amphipathic helices that protect RsiV from signal peptidase cleavage in the absence of lysozyme.
Disruption of the putative amphipathic helices forces hydrophobic residues out of the membrane
We have shown that changing hydrophobic residues of the amphipathic helix to lysine leads to constitutive cleavage of RsiV and that cysteine substitutions in the hydrophobic face are not accessible in the absence of lysozyme. To measure the effects of the lysine mutations on accessibility of the hydrophobic face we combined I80K with different hydrophobic cysteine substitutions (V72C, I76C) and analyzed these strains using the SCAM assay in the presence and absence of lysozyme. As we showed previously RsiVV72C and RsiVI76C did not label in absence of lysozyme and upon the addition of lysozyme they were labeled by MPB (Fig 6). Interestingly, the cysteines in RsiVV72C, I80K and RsiVI76C, I80K were accessible to MPB labelling in both the presence and absence of lysozyme (Fig 6). This suggests the hydrophobic face is no longer in the membrane when there is a lysine substitution. This result is consistent with the model of lysine substitutions in the hydrophobic face of the amphipathic helix displacing the helix from the membrane and leading to constitutive cleavage of RsiV and thus constitutive σV activation.
Discussion
Here we describe a mechanism by which RsiV resists signal peptidase cleavage in the absence of lysozyme and propose a model for how lysozyme binding to RsiV leads to degradation of the anti-σ factor and subsequent activation of σV. We propose that RsiV contains amphipathic helices immediately after the transmembrane domain that interact with the membrane and restrict signal peptidase access to the cleavage site, leading to a stable protein in the absence of signal. This is supported by: 1) this region is necessary and sufficient to protect from signal peptidase cleavage 2) disruption of hydrophobic residues by lysine substitution leads to constitutive activation of σV and 3) hydrophobic residues remain unlabeled in the absence of lysozyme. We also propose that lysozyme binding to RsiV leads to a conformational change that drives the amphipathic helices from the membrane, allowing signal peptidase to access the cleavage site. This model is supported by the differential labeling of residues on the hydrophobic face of the amphipathic helix.
Putative amphipathic helices provide resistance from signal peptidase cleavage
Our data suggests the presence of amphipathic helices that are required for the protection of RsiV from signal peptidase cleavage. The fusion construct RsiV1-86-GFP demonstrates that this region is sufficient to block signal peptidase cleavage, whereas fewer residues fail to protect. Deletions of this region lead to both constitutive cleavage of RsiV and constitutive σV activity showing that this region is necessary to resist signal peptidase cleavage. This study also found that disrupting the hydrophobicity of the amphipathic helices through lysine substitution abolished protection from signal peptidase cleavage. The sensitivity to signal peptidase cleavage is likely due to the lysine substitutions forcing the helices out of the membrane and is supported by the observation that a lysine substitution leads to accessibility of the hydrophobic face in the absence of lysozyme.
The results of the cysteine labeling assay show that in the absence of lysozyme, residues on the hydrophobic face of the amphipathic helix are inaccessible to label. This suggests these helices are either membrane-associated, interacting with each other via the hydrophobic faces, or the hydrophobic residues are buried inside of RsiV. Our observation that RsiV1-86-GFP, which lacks the majority of extracellular RsiV, yet is protected from signal peptidase cleavage implies that the amphipathic helices are not interacting with RsiV. Thus, we favor a model where they interact with the membrane or with one another via their hydrophobic surfaces thus protecting them from signal peptidase cleavage.
Lysozyme binding drives amphipathic helices out of the membrane
Our lab has previously shown that lysozyme binds to RsiV and we have obtained the crystal structure of this complex [42]. We have also shown that the binding of lysozyme to RsiV is necessary for signal peptidase to cleave RsiV [37,38,42]. Previously it has been hypothesized that the binding of lysozyme to RsiV induces a conformation change leading to the susceptibility of signal peptidase cleavage. We propose that binding of lysozyme to RsiV causes the amphipathic helices to no longer interact with the membrane, allowing signal peptidase access to the previously sequestered signal peptide cleavage site. This model is supported by the observation that residues which we presume to interact with membrane in the absence of lysozyme become accessible when lysozyme binds to RsiV.
One major question remains: what drives α-helices from the membrane upon lysozyme binding? Signal peptidases preferentially cleave flexible and accessible regions of a protein over ordered structures such as α-helices [53]. The co-structure of RsiV and lysozyme shows that residues 79–89 are in a β-sheet while residues 59–78 are disordered when bound to lysozyme [42]. In the absence of lysozyme, however, residue 80 is unable to be labeled by a membrane-impermeable dye, suggesting it is membrane embedded. The latter is supported by structural prediction programs which propose amphipathic helices for region 61–79. Thus, one possible mechanism responsible for driving the amphipathic helices from the membrane is that lysozyme binding causes part of the helix to convert to a β-sheet. A structure of RsiV alone is needed to answer these questions.
Additional examples of amphipathic helices controlling degradation
There are other reports of amphipathic helices controlling degradation or cleavage of proteins by signal peptidases. One example is the HIV glycoprotein 160 (gp160) which is processed in the endoplasmic reticulum of infected cells and forms the soluble subunit gp120 which is involved in viral entry [54,55]. Once gp160 is translocated across the ER membrane, an α-helix surrounding the signal peptidase cleavage site interacts with the ER membrane and prevents cleavage until the protein is properly folded [56]. This α-helix works as a quality control mechanism to ensure proper folding prior to signal peptidase cleavage. In fact when the α-helix is disrupted, proper folding does not occur [56].
Another example of an amphipathic helix controlling degradation is the human protein squalene monooxygenase (SM) which is the second, rate-limiting step in cholesterol biosynthesis [57]. When cholesterol levels are low, the amphipathic helix of SM is associated with the ER membrane and SM is able to function normally. Once cholesterol levels rise, the amphipathic helix is disassociated from the membrane likely due to cholesterol thickening and flattening of the ER membrane. This disassociation leads to the degradation of SM by the ubiquitin–proteasome system and leads to a decrease in cholesterol biosynthesis [58]. These systems are similar to RsiV in that they all use a membrane-associated amphipathic helix to control the access of a protease to its cleavage site resulting in blocking or delaying cleavage. These observations may suggest a broader use of amphipathic helices in controlling the cleavage of other as yet unidentified signal peptidase substrates.
DUF4179 contains putative amphipathic helices
The transmembrane segment and putative amphipathic helices of RsiV are part of a domain of unknown function, DUF4179 [48]. This domain is found primarily in Firmicutes and a crystal structure has been solved for a protein containing this domain. The crystal structure (3FBQ) is the extracellular domain of an ECF anti-σ factor from B. anthracis [49]. The structure shows a region directly after the transmembrane domain that has two short α-helices similar to the predicted structure of the region surrounding the RsiV cleavage site. However, the rest of the protein is unrelated to RsiV. This structural information, combined with the results of our study, and the role of amphipathic helices controlling signal peptidase cleavage in other organisms raises the intriguing possibility that this could be a common motif in ECF signaling, playing an important role in protecting the anti-σ factor from degradation, and triggering the proteolytic cascade that releases the cognate σ-factor in the presence of the appropriate signal.
Materials and methods
Strain construction
All B. subtilis strains (Table 2) are isogenic derivatives of PY79, a prototrophic derivative of B. subtilis strain 168 [59]. Plasmids used in this study are listed in Table 3 and were confirmed by DNA sequencing (Iowa State DNA Sequencing Facility). B. subtilis strains were transformed using a one-step method to induce competence previously described by [60]. Plasmids used for transformation into B. subtilis were first created using site directed mutagenesis (Supplemental Methods) along with isothermal assembly [61] and propagated in E. coli Omnimax cells. Oligonucleotide primers used for PCR and site-directed mutagenesis are listed in S1 Table.
Table 2. Strains list.
Strains | Genotype | Reference |
---|---|---|
E. coli strains | ||
Omni Max | F´ {proAB lacIq lacZΔM15 Tn10(TetR) Δ(ccdAB)} mcrA Δ(mrr hsdRMS-mcrBC) Φ 80(lacZ)ΔM15 Δ(lacZYA- argF)U169 endA1 recA1 supE44 thi-1 gyrA96 relA1 tonA panD | Invitrogen |
BL21λDE3 | E. coli fhuA2 [lon] ompT gal (λ DE3) [dcm] ΔhsdS λDE3 (sBamHIo ΔEcoRI-B int::(DE3) (lacI::PlacUV5::T7 gene1) i21 Δnin5) | Invitrogen |
ANC108 | BL21λDE3/pAC108 (pET21b 6xhis-rsiV+) | [38] |
LTL408 | BL21λDE3/pLL190 (pET21b 6xhis-rsiVA66W) | |
LTL410 | BL21λDE3/pLL192 (pET21b 6xhis-rsiVA66W I76K) | |
LTL411 | BL21λDE3/pLL193 (pET21b 6xhis-rsiVA66W I80K) | |
B. subtilis strains | ||
PY79 | Prototrophic derivative of B. subtilis 168 | [59] |
CDE1936 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) | |
CDE1563 | ΔsigVrsiV::kn | [16] |
LTL172 | ΔsigVrsiV::kn amyE::Phs-rsiV(spec) pLL101 | |
LTL423 | ΔsigVrsiV::kn amyE::Phs-rsiV1-66-gfp(spec) pLL197 | |
LTL424 | ΔsigVrsiV::kn amyE:: Phs -rsiV1-76-gfp(spec) pLL194 | |
LTL425 | ΔsigVrsiV::kn amyE:: Phs -rsiV1-86-gfp(spec) pLL195 | |
LTL426 | ΔsigVrsiV::kn amyE:: Phs -rsiV1-96-gfp(spec) pLL196 | |
LTL144 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiV(erm) pLL114 | |
LTL253 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVI73K(erm) pLL201 | |
LTL254 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVI76K(erm) pLL140 | |
LTL255 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVI80K(erm) pLL141 | |
LTL430 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVM670K(erm) pLL198 | |
LTL456 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVΔ67-76(erm) pLL208 | |
LTL457 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVΔ67-86(erm) pLL209 | |
LTL464 | ΔsigVrsiV::kn amyE:: Phs -rsiVΔ67-76(spec) pLL212 | |
LTL465 | ΔsigVrsiV::kn amyE:: Phs -rsiVΔ67-86(spec) pLL213 | |
LTL279 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W(spec) pLL158 | |
LTL280 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVQ65C A66W(spec) pLL159 | |
LTL433 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W M67C(spec)pLL185 | |
LTL437 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W K69C(spec) pLL202 | |
LTL356 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W I70C(spec) pLL182 | |
LTL438 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W V72C(spec) pLL203 | |
LTL318 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W I73C(spec) pLL165 | |
LTL319 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W I76C(spec) pLL167 | |
LTL348 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W K78C(spec) pLL179 | |
LTL357 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W I80C(spec) pLL193 | |
LTL358 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W F82C(spec) pLL184 | |
LTL316 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W E84C(spec) pLL168 | |
LTL315 | ΔsigVrsiV::kn amyE:: Phs -6xhis-rsiVA66W A167C(spec) pLL169 | |
LTL474 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVQ65C(erm) pLL215 | |
LTL475 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVM67C(erm) pLL216 | |
LTL476 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVK69C(erm) pLL217 | |
LTL477 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVI70C(erm) pLL218 | |
LTL478 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVV72C(erm) pLL219 | |
LTL450 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVI73C(erm) pLL205 | |
LTL271 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVI76C(erm) pLL153 | |
LTL510 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVK78C(erm) pLL206 | |
LTL452 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVI80C(erm) pLL207 | |
LTL479 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVF82C(erm) pLL220 | |
LTL273 | ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat) thrC::PsigV-sigVrsiVE84C(erm) pLL155 | |
LTL503 | ΔsigVrsiV::kn amyE:: Phs -6xHis-rsiVA66W V72C I80K(spec) pLL222 | |
LTL504 | ΔsigVrsiV::kn amyE:: Phs -6xHis-rsiVA66W I76C I80K(spec) pLL223 |
Table 3. Plasmid list.
Plasmid | Features | Reference |
---|---|---|
pDR111 | amyE Phs Ampr Specr | [68] |
pDG1664 | thrC Ampr Ermr Specr | [69] |
pCM11 | sGFP | [62] |
pET21b | Ampr, N terminal-6xhis expression vector, T7 promoter | |
pCE544 | pDR111 6xhis-rsiV | |
pLL190 | pET21b rsiVA66W | |
pLL192 | pET21b rsiVA66W I76K | |
pLL193 | pET21b rsiVA66W I80K | |
pLL101 | pDR111 amyE::Phs-rsiV(spec) | |
pLL197 | pDR111 amyE::Phs-rsiV1-66-gfp(spec) | |
pLL194 | pDR111 amyE::Phs-rsiV1-76-gfp(spec) | |
pLL195 | pDR111 amyE:: Phs-rsiV1-86-gfp(spec) | |
pLL196 | pDR111 amyE:: Phs-rsiV1-96-gfp(spec) | |
pLL114 | pDG1664 thrC::PsigV-sigVrsiV(erm) | |
pLL201 | pDG1664 thrC:: PsigV -sigVrsiVI73K(erm) | |
pLL140 | pDG1664 thrC:: PsigV -sigVrsiVI76K(erm) | |
pLL141 | pDG1664 thrC:: PsigV -sigVrsiVI80K(erm) | |
pLL198 | pDG1664 thrC:: PsigV -sigVrsiVM67K(erm) | |
pLL208 | pDG1664 thrC:: PsigV -sigVrsiVΔ67-76(erm) | |
pLL209 | pDG1664 thrC:: PsigV -sigVrsiVΔ67-86(erm) | |
pLL212 | pDR111 amyE:: Phs -rsiVΔ67-76(spec) | |
pLL213 | pDR111 amyE:: Phs -rsiVΔ67-86(spec) | |
pLL158 | pDR111 amyE:: Phs -6xhis-rsiVA66W(spec) | |
pLL159 | pDR111 amyE:: Phs -6xhis-rsiVQ65C A66W(spec) | |
pLL185 | pDR111 amyE:: Phs -6xhis-rsiVA66W M67C(spec) | |
pLL202 | pDR111 amyE:: Phs -6xhis-rsiVA66W K69C(spec) | |
pLL182 | pDR111 amyE:: Phs -6xhis-rsiVA66W I70C(spec) | |
pLL203 | pDR111 amyE:: Phs -6xhis-rsiVA66W V72C(spec) | |
pLL165 | pDR111 amyE:: Phs -6xhis-rsiVA66W I73C(spec) | |
pLL167 | pDR111 amyE:: Phs -6xhis-rsiVA66W I76C(spec) | |
pLL179 | pDR111 amyE:: Phs -6xhis-rsiVA66W K78C(spec) | |
pLL193 | pDR111 amyE:: Phs -6xhis-rsiVA66W I80C(spec) | |
pLL184 | pDR111 amyE:: Phs -6xhis-rsiVA66W F82C(spec) | |
pLL168 | pDR111 amyE:: Phs -6xhis-rsiVA66W E84C(spec) | |
pLL169 | pDR111 amyE:: Phs -6xhis-rsiVA66W A167C(spec) | |
pLL215 | pDG1664 thrC:: PsigV -sigVrsiVQ65C(erm) | |
pLL216 | pDG1664 thrC:: PsigV -sigVrsiVM67C(erm) | |
pLL217 | pDG1664 thrC:: PsigV -sigVrsiVK69C(erm) | |
pLL218 | pDG1664 thrC:: PsigV -sigVrsiVI70C(erm) | |
pLL219 | pDG1664 thrC:: PsigV -sigVrsiVV72C(erm) | |
pLL205 | pDG1664 thrC:: PsigV -sigVrsiVI73C(erm) | |
pLL153 | pDG1664 thrC:: PsigV -sigVrsiVI76C(erm) | |
pLL206 | pDG1664 thrC:: PsigV -sigVrsiVK78C(erm) | |
pLL207 | pDG1664 thrC:: PsigV -sigVrsiVI80C(erm) | |
pLL220 | pDG1664 thrC:: PsigV -sigVrsiVF82C(erm) | |
pLL155 | pDG1664 thrC:: PsigV -sigVrsiVE84C(erm) | |
pLL222 | pDR111 amyE::Phs-6xHis-rsiVA66W V72C I80K(spec) | |
pLL223 | pDR111 amyE::Phs-6xHis-rsiVA66W I76C I80K(spec) |
Constructs were cloned into pDR111 in order to place rsiV variants under control of the IPTG-inducible hyper-spank (Phs) promoter. The vector, pDR111 was digested with HindIII and SphI and PCR products were introduced by isothermal assembly. All pDR111 constructs were transformed into CDE1563 (ΔsigVrsiV::kn) and the RsiV construct was introduced at the amyE gene on the chromosome. WT RsiV was created using CDEP3194/CDEP3195 (chromosomal DNA). Rsiv-GFP fusion construct inserts were created using CDEP3865/Appropriate RsiV-GFP Reverse (Rev) primer (chromosomal DNA) and CDEP3868/Appropriate RsiV-GFP Forward (For) primer (pCM11 template) [62]. RsiV deletion constructs were created using CDEP3194/Appropriate RsiVΔ Rev primer (chromosomal DNA) and CDEP3195/Appropriate RsiVΔ For primer. SCAM constructs were created by first building 6xHis-rsiVA66W using primers CDEP3629/A66W Rev (chromosomal DNA) and CDEP3195/A66W For (chromosomal DNA). The remaining SCAM constructs were created using 6xHis-rsiVA66W as template. The inserts were created with primers CDEP3629/Appropriate rsiV For primer and CDEP3195/Appropriate rsiV Rev.
Constructs cloned onto pDG1664 were created by first digesting the vector with BamHI and EcoRI to allow for Isothermal Assembly of the PCR products. All pDG1664 constructs were transformed into CDE1936 (ΔsigVrsiV::kn pyrD::PsigV-lacZ(cat)) and the sigVrsiV constructs were introduced at the thrC gene on the chromosome. WT sigVrsiV was created using primers CDEP3533/CDEP3534 (sigVrsiV template). Deletions constructs, lysine substitutions, and cysteine mutations in the reporter strain were created with the primers CDEP3533/Appropriate rsiV Rev and CDEP3534/Appropriate rsiV For (sigVrsiV template).
Constructs cloned onto pET21b were created by first digesting the vector with BamHI and NdeI to allow for Isothermal Assembly of the PCR products. All pET21b constructs were transformed into E. coli BL21λDE3. ANC108 (pET21b 6xhis-rsiV)[38] was used as the initial template to create the constructs. First, we generated 6xhis-rsiVA66W using the primers CDEP3165/1562 and CDEP3267/CDEP1561. We then used 6xhis-rsiVA66W as template to create 6xhis-rsiVA66W I76K and 6xhis-rsiVA66W I80K using the primers CDEP3165/Appropriate rsiV Rev and CDEP3267/Appropriate rsiV For.
Media supplements
Antibiotics were used at the following concentrations: chloramphenicol, 5 μg/ml; MLS erythromycin plus lincomycin, 1 μg/ml and 25 μg/ml; kanamycin, 5 μg/ml; spectinomycin, 100 μg/ml; ampicillin 100 μg/ml. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was used at a final concentration of 1 mM unless otherwise noted.
Protein expression and concentration
Cell cultures were grown overnight in LB broth at 37°C and subcultured 1:100 in 5 mL LB IPTG (1mM). Cells were incubated at 37°C for ~3hrs to an OD600 of 0.8–1 and 1 mL of cell culture was centrifuged to obtain a pellet and supernatant. The proteins in the supernatant were precipitated with methanol chloroform [63] and the resulting precipitant was analyzed by western blotting. The culture pellet was resuspended in 100 μL LB with or without lysozyme (10 μg/mL) and incubated at room temperature. After 10 min, 100 μL 2x Laemmli sample buffer was added to stop the reaction. Cells were sonicated with a Branson Sonifier 450 and analyzed by western blotting.
β-galactosidase assay
Cells were grown in LB (1% NaCl) to inhibit lysozyme activity [64]. ON cells were subcultured 1:20 and grown at 37°C for 2 hrs. These early log-phase cultures were then diluted to an OD600 of 0.05 and grown in 200 μL volumes in a round bottom 96-well plate in the presence of varied concentrations of lysozyme (0, 5, and 10 μg/mL). The plate was shaken at 1000 rpm at 37°C for 4 hrs. The cell density (OD600) was determined by diluting 50 μL from each well into 150 μL LB in a 96-well flat bottom plate. The remainder of each culture was lysed by mixing with 6 μL 2% sarkosyl, 12 μL chloroform. Lysate (20 μL) was added to 100 μL Z-buffer (60mM Na2HPO4, 40mM NaH2PO4, 10mM KCl, 1mM MgSO4, 50mM 2-mercaptoethanol, pH 7.0) in a flat bottom 96-well plate. The reaction was started by the addition of 50 μL ONPG (10 μg/mL) and color development followed at 405 nm, every 1 min for 30 min (Tecan Infinite M200 Pro). β-galactosidase activity was reported as the rate of product development normalized to cell density.
SCAM assay
This protocol was adapted from [65]. Cells cultures were grown overnight in LB broth at 37°C and subcultured 1:100 in 50 mL LB IPTG. Cells were incubated at 37°C for ~3hrs to an OD600 of 0.8–1 and 15 mL cell cultures were centrifuged and pellets resuspended in 500 μL protoplast buffer (0.4 M sucrose, 10 mM KPi, 15 mM MgCl2) [66] with and without lysozyme (75 μg/mL) and incubated at room temperature. After 10 minutes Na-(3-maleimidylpropionyl) biocytin (MPB, Invitrogen) (50 μM) was added to label cysteine residues. The reaction was quenched by the addition of 2-mercaptoethanol to a final concentration 20 mM. Cells were washed with protoplast buffer amended with 2-mercaptoethanol (20 mM).
Labeled RsiV variants were then affinity purified as described below, with volumes adjusted to the smaller scale: 50 μL nickel resin, 500 μL lysis buffer, 500 μL wash buffer, and 50 μL elution buffer. The eluted protein was immediately mixed with 50 μL 2X Laemmli buffer and analyzed by immunoblotting.
Immunoblot analysis
Samples were electrophoresed on a 15% SDS polyacrylamide gel (Biorad) and proteins were then blotted onto a nitrocellulose membrane (GE Healthcare, Amersham). Nitrocellulose was blocked with 5% Bovine Serum Albumin (BSA) and proteins were detected with either 1:10,000 dilution anti-RsiV59-285 [16] or anti-GFP. Streptavidin IR680LT (1:2500) was used to detect two biotin-containing proteins, PycA and AccB, which serve as loading controls [67]. To detect primary antibodies, nitrocellulose was washed and incubated with 1:10,000 dilution of Goat anti-Rabbit IR800CW (Li-Cor) and imaged on an Odyssey CLx Scanner (Li-Cor). All immunoblots were performed a minimum of three times with a representative example shown.
Protein purification
Expression cultures of RsiV variants were prepared as previously described [37]. Briefly, 50 mL of LB Amp100 was inoculated 1:100 with overnight cultures of BL21(DE3) harboring the respective expression plasmids, grown shaking at 37°C to an OD600 of 0.8, induced with 1 mM IPTG and shifted to 30°C. After 3 hours of growth, cells were pelleted by centrifugation. RsiV variants included a 6xHis-tag at the N-terminus and were affinity purified over Nickel resin (Thermo HisPur Ni-NTA, Cat Nr 88222). Batch purification was performed in 50 mM TrisHCl, pH 8.0, 250 mM NaCl, all steps at 4°C. Lysis buffer, wash buffer and elution buffer included 10 mM, 20 mM and 250 mM imidazole, respectively. Nickel resin (500 μL slurry) was equilibrated with lysis buffer. Cell pellets were lysed in 2 mL lysis buffer by sonication (Branson Sonifier 450, microtip, output 3, three cycles of 30 pulses) and the lysate was clarified by spinning at 30 min 16,000 x g. The supernatant was incubated with the prepared resin for 20 min, washed five times with 2 mL wash buffer and protein was eluted in two 1 mL fractions. The fractions were combined and dialyzed against 50 mM NaPi, pH 7.0, 100 mM NaCl.
Circular dichroism
CD spectroscopy to determine protein secondary structure was performed with about 10 μM protein in 50 mM NaPi, pH 7.0, 100 mM NaCl. CD spectra were recorded from 260 nm to 190 nm with 1 nm data interval at 25°C in a Jasco J-815 CD spectropolarimeter. Data integration time was 2 seconds and the scanning speed was 100 nm/min. For comparison to WT protein, spectra were normalized to the signal at 220 nm.
Supporting information
Acknowledgments
We would like to thank members of the Ellermeier lab for helpful comments.
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
This work was supported by National Institutes of Health grant R01AI087834 from the National Institutes for Allergy and Infectious Disease to CDE. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Staroń A, Sofia HJ, Dietrich S, Ulrich LE, Liesegang H, Mascher T. The third pillar of bacterial signal transduction: classification of the extracytoplasmic function (ECF) sigma factor protein family. Mol Microbiol. 2009;74: 557–81. 10.1111/j.1365-2958.2009.06870.x [DOI] [PubMed] [Google Scholar]
- 2.Sineva E, Savkina M, Ades SE. Themes and variations in gene regulation by extracytoplasmic function (ECF) sigma factors. Curr Opin Microbiol. 2017;36: 128–137. 10.1016/j.mib.2017.05.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Helmann JD. Bacillus subtilis extracytoplasmic function (ECF) sigma factors and defense of the cell envelope. Curr Opin Microbiol. 2016;30: 122–132. 10.1016/j.mib.2016.02.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ho TD, Ellermeier CD. Extra cytoplasmic function σ factor activation. Curr Opin Microbiol. 2012;15: 182–8. 10.1016/j.mib.2012.01.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Radeck J, Fritz G, Mascher T. The cell envelope stress response of Bacillus subtilis: from static signaling devices to dynamic regulatory network. Curr Genet. 2016; [DOI] [PubMed] [Google Scholar]
- 6.Zdanowski K, Doughty P, Jakimowicz P, O’Hara L, Buttner MJ, Paget MSB, et al. Assignment of the zinc ligands in RsrA, a redox-sensing ZAS protein from Streptomyces coelicolor. Biochemistry. 2006;45: 8294–8300. 10.1021/bi060711v [DOI] [PubMed] [Google Scholar]
- 7.Li W, Stevenson CEM, Burton N, Jakimowicz P, Paget MSB, Buttner MJ, et al. Identification and Structure of the Anti-sigma Factor-binding Domain of the Disulphide-stress Regulated Sigma Factor σR from Streptomyces coelicolor. J Mol Biol. 2002;323: 225–236. [DOI] [PubMed] [Google Scholar]
- 8.Dufour YS, Landick R, Donohue TJ. Organization and Evolution of the Biological Response to Singlet Oxygen Stress. J Mol Biol. 2008;383: 713–730. 10.1016/j.jmb.2008.08.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Greenwell R, Nam TW, Donohue TJ. Features of Rhodobacter sphaeroides ChrR required for stimuli to promote the dissociation of σE/ChrR complexes. J Mol Biol. 2011;407: 477–491. 10.1016/j.jmb.2011.01.055 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Francez-Charlot A, Frunzke J, Reichen C, Ebneter JZ, Gourion B, Vorholt JA. Sigma factor mimicry involved in regulation of general stress response. Proc Natl Acad Sci. 2009;106: 3467–3472. 10.1073/pnas.0810291106 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Campagne S, Damberger FF, Kaczmarczyk A, Francez-Charlot A, Allain FH-T, Vorholt JA. Structural basis for sigma factor mimicry in the general stress response of Alphaproteobacteria. Proc Natl Acad Sci. 2012;109: E1405–E1414. 10.1073/pnas.1117003109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Herrou J, Foreman R, Fiebig A, Crosson S. A structural model of anti-anti-σ inhibition by a two-component receiver domain: the PhyR stress response regulator. Mol Microbiol. 2010;78: 290–304. 10.1111/j.1365-2958.2010.07323.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Herrou J, Rotskoff G, Luo Y, Roux B, Crosson S. Structural basis of a protein partner switch that regulates the general stress response of α-proteobacteria. Proc Natl Acad Sci. 2012;109: E1415–E1423. 10.1073/pnas.1116887109 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Paget M. Bacterial Sigma Factors and Anti-Sigma Factors: Structure, Function and Distribution. Biomolecules. 2015;5: 1245–1265. 10.3390/biom5031245 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Mascher T. Signaling diversity and evolution of extracytoplasmic function (ECF) σ factors. Curr Opin Microbiol. 2013;16: 148–155. 10.1016/j.mib.2013.02.001 [DOI] [PubMed] [Google Scholar]
- 16.Hastie JL, Williams KB, Ellermeier CD. The activity of σV, an Extra-Cytoplasmic Function σ factor of Bacillus subtilis, is controlled by a regulated proteolysis of the anti-σ factor RsiV. J Bacteriol. 2013;195: 3135–3144. 10.1128/JB.00292-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Schöbel S, Zellmeier S, Schumann W, Wiegert T. The Bacillus subtilis σW anti-sigma factor RsiW is degraded by intramembrane proteolysis through YluC. Mol Microbiol. 2004;52: 1091–105. 10.1111/j.1365-2958.2004.04031.x [DOI] [PubMed] [Google Scholar]
- 18.Ades SE, Connolly LE, Alba BM, Gross CA. The Escherichia coli σE-dependent extracytoplasmic stress response is controlled by the regulated proteolysis of an anti-σ factor. Genes Dev. 1999;13: 2449–61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Chaba R, Grigorova IL, Flynn JM, Baker TA, Gross CA. Design principles of the proteolytic cascade governing the σE-mediated envelope stress response in Escherichia coli: keys to graded, buffered, and rapid signal transduction. Genes Dev. 2007; 124–136. 10.1101/gad.1496707 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Mecsas J, Rouviere PE, Erickson JW, Donohue TJ, Gross CA. The activity of sigma E, an Escherichia coli heat-inducible sigma-factor, is modulated by expression of outer membrane proteins. Genes Dev. 1993;7: 2618–2628. [DOI] [PubMed] [Google Scholar]
- 21.Walsh NP, Alba BM, Bose B, Gross CA, Sauer RT. OMP peptide signals initiate the envelope-stress response by activating DegS protease via relief of inhibition mediated by its PDZ domain. Cell. 2003;113: 61–71. [DOI] [PubMed] [Google Scholar]
- 22.Kanehara K, Ito K, Akiyama Y. YaeL (EcfE) activates the σE pathway of stress response through a site-2 cleavage of anti-σE, RseA. Genes Dev. 2002;16: 2147–2155. 10.1101/gad.1002302 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Ellermeier CD, Losick R. Evidence for a novel protease governing regulated intramembrane proteolysis and resistance to antimicrobial peptides in Bacillus subtilis. Genes Dev. 2006;20: 1911–22. 10.1101/gad.1440606 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Heinrich J, Wiegert T. YpdC determines site-1 degradation in regulated intramembrane proteolysis of the RsiW anti-sigma factor of Bacillus subtilis. Mol Microbiol. 2006;62: 566–79. 10.1111/j.1365-2958.2006.05391.x [DOI] [PubMed] [Google Scholar]
- 25.Ho TD, Hastie JL, Intile PJ, Ellermeier CD. The Bacillus subtilis extracytoplasmic function σ factor σV is induced by lysozyme and provides resistance to lysozyme. J Bacteriol. 2011;193: 6215–22. 10.1128/JB.05467-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Callewaert L, Michiels CW. Lysozymes in the animal kingdom. J Biosci. 2010;35: 127–160. [DOI] [PubMed] [Google Scholar]
- 27.Ragland SA, Criss AK. From bacterial killing to immune modulation: Recent insights into the functions of lysozyme. PLOS Pathog. 2017;13: e1006512 10.1371/journal.ppat.1006512 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Salton MRJ. the Properties of Lysozyme and Its Action on Microorganisms. Bacteriol Rev. 1957;21: 82–100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Laaberki M-H, Pfeffer J, Clarke AJ, Dworkin J. O-Acetylation of peptidoglycan is required for proper cell separation and S-layer anchoring in Bacillus anthracis. J Biol Chem. 2011;286: 5278–88. 10.1074/jbc.M110.183236 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Herbert S, Bera A, Nerz C, Kraus D, Peschel A, Goerke C, et al. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 2007;3: e102 10.1371/journal.ppat.0030102 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Guariglia-Oropeza V, Helmann JD. Bacillus subtilis σV Confers Lysozyme Resistance by Activation of Two Cell Wall Modification Pathways, Peptidoglycan O-Acetylation and d-Alanylation of Teichoic Acids. J Bacteriol. 2011;193: 6223–6232. 10.1128/JB.06023-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.McBride SM, Sonenshein AL. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology. 2011;157: 1457–65. 10.1099/mic.0.045997-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Woods EC, Nawrocki KL, Suárez JM, McBride SM. The Clostridium difficile Dlt pathway is controlled by the extracytoplasmic function sigma factor σvin response to lysozyme. Infect Immun. 2016;84: 1902–1916. 10.1128/IAI.00207-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Collins LV, Kristian SA, Weidenmaier C, Faigle M, Van Kessel KPM, Van Strijp JAG, et al. Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J Infect Dis. 2002;186: 214–9. 10.1086/341454 [DOI] [PubMed] [Google Scholar]
- 35.Benachour A, Muller C, Dabrowski-Coton M, Le Breton Y, Giard J-C, Rincé A, et al. The Enterococcus faecalis SigV protein is an extracytoplasmic function sigma factor contributing to survival following heat, acid, and ethanol treatments. J Bacteriol. 2005;187: 1022–35. 10.1128/JB.187.3.1022-1035.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Ho TD, Williams KB, Chen Y, Helm RF, Popham DL, Ellermeier CD. Clostridium difficile extracytoplasmic function σfactor σV regulates lysozyme resistance and is necessary for pathogenesis in the hamster model of infection. Infect Immun. 2014;82: 2345–2355. 10.1128/IAI.01483-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Hastie JL, Williams KB, Sepúlveda C, Houtman JC, Forest KT, Ellermeier CD. Evidence of a Bacterial Receptor for Lysozyme: Binding of Lysozyme to the Anti-σ Factor RsiV Controls Activation of the ECF σ Factor σV. PLoS Genet. 2014;10: e1004643 10.1371/journal.pgen.1004643 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Castro AN, Lewerke LT, Hastie JL, Ellermeier CD. Signal peptidase is necessary and sufficient for site-1 cleavage of RsiV in Bacillus subtilis in response to lysozyme. J Bacteriol. 2018;200: JB.00663-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.van Roosmalen ML, Geukens N, Jongbloed JDH, Tjalsma H, Dubois J-YF, Bron S, et al. Type I signal peptidases of Gram-positive bacteria. Biochim Biophys Acta. 2004;1694: 279–97. 10.1016/j.bbamcr.2004.05.006 [DOI] [PubMed] [Google Scholar]
- 40.Dalbey RE, Lively MO, Bron S, van Dijl JM. The chemistry and enzymology of the type I signal peptidases. Protein Sci. 1997;6: 1129–38. 10.1002/pro.5560060601 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Wang Y, Bruckner R, Stein RL. Regulation of signal peptidase by phospholipids in membrane: characterization of phospholipid bilayer incorporated Escherichia coli signal peptidase. Biochemistry. 2004;43: 265–270. 10.1021/bi034535r [DOI] [PubMed] [Google Scholar]
- 42.Hastie JL, Williams KB, Bohr LL, Houtman JC, Gakhar L, Ellermeier CD. The Anti-sigma Factor RsiV Is a Bacterial Receptor for Lysozyme: Co-crystal Structure Determination and Demonstration That Binding of Lysozyme to RsiV Is Required for σV Activation. Burkholder WF, editor. PLOS Genet. 2016;12: e1006287 10.1371/journal.pgen.1006287 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 2009;37: W202–8. 10.1093/nar/gkp335 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Crooks GE, Hon G, Chandonia J-M, Brenner SE. WebLogo: a sequence logo generator. Genome Res. 2004;14: 1188–90. 10.1101/gr.849004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tufféry P. PEP-FOLD: An updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 2012;40: 288–293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Shen Y, Maupetit J, Derreumaux P, Tufféry P. Improved PEP-FOLD approach for peptide and miniprotein structure prediction. J Chem Theory Comput. 2014;10: 4745–4758. 10.1021/ct500592m [DOI] [PubMed] [Google Scholar]
- 47.Mól AR, Castro, M S, Fontes W. NetWheels: A web application to create high quality peptide helical wheel and net projections. 2016. http://lbqp.unb.br/NetWheels/
- 48.Finn RD, Bateman A, Clements J, Coggill P, Eberhardt RY, Eddy SR, et al. Pfam: The protein families database. Nucleic Acids Res. 2014;42: 290–301. 10.1093/nar/gkt830 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Zhang R, Joachimiak G, Kim Y, Gornicki P, Joachimiak A. The crystal structure of the conserved domain protein from Bacillus anthracis. 10.2210/pdb3FBQ/pdb [DOI] [Google Scholar]
- 50.Slotboom DJ, Konings WN, Lolkema JS. Cysteine-scanning Mutagenesis Reveals a Highly Amphipathic, Pore-lining Membrane-spanning Helix in the Glutamate Transporter GltT. J Biol Chem. 2001;276: 10775–10781. 10.1074/jbc.M011064200 [DOI] [PubMed] [Google Scholar]
- 51.Bogdanov M, Zhang W, Xie J, Dowhan W. Transmembrane protein topology mapping by the substituted cysteine accessibility method (SCAM): Application to lipid-specific membrane protein topogenesis. Methods. 2005;36: 148–171. 10.1016/j.ymeth.2004.11.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Zhu Q, Casey JR. Topology of transmembrane proteins by scanning cysteine accessibility mutagenesis methodology. Methods. 2007;41: 439–450. 10.1016/j.ymeth.2006.08.004 [DOI] [PubMed] [Google Scholar]
- 53.Auclair SM, Bhanu MK, Kendall DA. Signal peptidase I: Cleaving the way to mature proteins. Protein Sci. 2012;21: 13–25. 10.1002/pro.757 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, et al. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell. 1988;53: 55–67. [DOI] [PubMed] [Google Scholar]
- 55.Willey RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A. 1988;85: 9580–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Snapp EL, McCaul N, Quandte M, Cabartova Z, Bontjer I, Källgren C, et al. Structure and topology around the cleavage site regulate post-translational cleavage of the HIV-1 gp160 signal peptide. Elife. 2017;6: e26067 10.7554/eLife.26067 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Gill S, Stevenson J, Kristiana I, Brown AJ. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. Cell Metab. 2011;13: 260–273. 10.1016/j.cmet.2011.01.015 [DOI] [PubMed] [Google Scholar]
- 58.Chua NK, Howe V, Jatana N, Thukral L, Brown AJ. A Conserved Degron Containing an Amphipathic Helix Regulates the Cholesterol-Mediated Turnover of Human Squalene Monooxygenase, a Rate-Limiting Enzyme in Cholesterol Synthesis. J Biol Chem. 2017; jbc.M117.794230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Youngman P, Perkins JB, Losick R. Construction of a cloning site near one end of Tn917 into which foreign DNA may be inserted without affecting transposition in Bacillus subtilis or expression of the transposon-borne erm gene. Plasmid. 1984;12: 1–9. [DOI] [PubMed] [Google Scholar]
- 60.Young FE. Competence in Bacillus subtilis transformation system. Nature. 1967;213: 773–775. [DOI] [PubMed] [Google Scholar]
- 61.Gibson DG, Young L, Chuang R, Venter JC, Hutchison CA, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6: 343–5. 10.1038/nmeth.1318 [DOI] [PubMed] [Google Scholar]
- 62.Lauderdale KJ, Malone CL, Boles BR, Morcuende J, Horswill AR. Biofilm dispersal of community-associated methicillin-resistant Staphylococcus aureus on orthopedic implant material. J Orthop Res. 2010;28: 55–61. 10.1002/jor.20943 [DOI] [PubMed] [Google Scholar]
- 63.Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem. 1984;138: 141–3. [DOI] [PubMed] [Google Scholar]
- 64.Chang KY, Carr CW. Studies on the structure and function of lysozyme. Biochim Biophys Acta—Protein Struct. 1971;229: 496–503. [DOI] [PubMed] [Google Scholar]
- 65.Thoendel M, Horswill AR. Random Mutagenesis and Topology Analysis of the Autoinducing Peptide Biosynthesis Proteins in Staphylococcus aureus. October 2013;89: 632–643. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Acid T. The Distribution of Lipids in the Protoplast Membranes of Bacillus subtilis. 1977;391: 381–391. [DOI] [PubMed] [Google Scholar]
- 67.Marini P, Li SJ, Gardiol D, Cronan JE, De Mendoza D. The genes encoding the biotin carboxyl carrier protein and biotin carboxylase subunits of Bacillus subtilis acetyl coenzyme a carboxylase, the first enzyme of fatty acid synthesis. J Bacteriol. 1995;177: 7003–7006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Ben-Yehuda S, Rudner DZ, Losick R. RacA, a bacterial protein that anchors chromosomes to the cell poles. Science (80-). 2003;299: 532–536. [DOI] [PubMed] [Google Scholar]
- 69.Guérout-Fleury AM, Frandsen N, Stragier P. Plasmids for ectopic integration in Bacillus subtilis. Gene. 1996;180: 57–61. [DOI] [PubMed] [Google Scholar]
- 70.Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol. 2011;7: 539 10.1038/msb.2011.75 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.